S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead ...
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...
Should You Buy the Dip in Eli Lilly Stock Right Now?
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...
Seeking Alpha11d
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Eli Lilly's operational performance is strong ... shares have seen downside of 14.8% at a time when the S&P 500 is up 2.6%. The picture isn't as bad when we compare the data to my original ...
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly’s drag
Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ...
Wall Street Journal9d
Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but Explore Our Brands ...
Nasdaq4d
Should You Buy the Dip in Eli Lilly Stock Right Now?
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE ... outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so ...